http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
View Older Stories
-
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
-
Cortexyme Successfully Completes Acquisition of Novosteo
-
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
-
Cortexyme (CRTX) to Acquire Novosteo
-
Cortexyme Announces Agreement to Acquire Novosteo
-
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
-
Cortexyme (CRTX) Appoints Marwan Sabbagh to its Board
-
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
-
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
-
Cortexyme (CRTX) Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders
-
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders
-
Cortexyme (CRTX) Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588
-
Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588
-
Cortexyme (CRTX) Announces Executive Leadership Team Changes
-
Cortexyme (CRTX) Issues Pipeline Update and Anticipated 2022 Milestones
-
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
-
Cortexyme Announces Change in Executive Leadership Team
-
Cortexyme (CRTX) Announces Clinical Hold on Atuzaginstat's Investigational New Drug Application
-
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
-
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
-
Cortexyme's (CRTX) Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
-
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
-
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
-
Pre-Open Stock Movers 10/27: (ENPH) (TENB) (FFIV) Higher; (CRTX) (HOOD) (TXN) Lower (more...)
-
After-Hours Stock Movers 10/26: (TENB) (JNPR) (TWTR) Higher; (CRTX) (HOOD) (ZIOP) Lower (more...)
-
Cortexyme (CRTX) 643-participant study in mild to moderate patients with Alzheimer’s disease did not meet statistical significance in its co-primary cognitive and functional endpoints
-
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
-
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
-
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
-
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
-
Cortexyme (CRTX) Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
-
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
-
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
-
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
-
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
-
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
-
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
-
Cortexyme to Present New Data at AAIC 2021
-
Cortexyme (CRTX) Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR
-
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
-
Cortexyme to Host Symposium at AAIC 2021
-
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat
-
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
-
Cortexyme to Present at Investor Conferences in June 2021
-
Cortexyme Provides Business Update and Reports First Quarter 2021 Results
-
Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021
-
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021
-
Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021
-
Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation
-
Cortexyme (CRTX) Reports Partial Clinical Hold on Development Program for Atuzaginstat in Alzheimer’s
